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Integrative analysis of the melanoma transcriptome
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Global studies of transcript structure and abundance in cancer cells enable the systematic discovery of aberrations that
contribute to carcinogenesis, including gene fusions, alternative splice isoforms, and somatic mutations. We developed
a systematic approach to characterize the spectrum of cancer-associated mRNA alterations through integration of
transcriptomic and structural genomic data, and we applied this approach to generate new insights into melanoma bi-
ology. Using paired-end massively parallel sequencing of cDNA (RNA-seq) together with analyses of high-resolution
chromosomal copy number data, we identified 11 novel melanoma gene fusions produced by underlying genomic rear-
rangements, as well as 12 novel readthrough transcripts. We mapped these chimeric transcripts to base-pair resolution and
traced them to their genomic origins using matched chromosomal copy number information. We also used these data to
discover and validate base-pair mutations that accumulated in these melanomas, revealing a surprisingly high rate of
somatic mutation and lending support to the notion that point mutations constitute the major driver of melanoma
progression. Taken together, these results may indicate new avenues for target discovery in melanoma, while also pro-
viding a template for large-scale transcriptome studies across many tumor types.
[Supplemental material is available online at http://www.genome.org. The sequencing and microarray data from this
study have been submitted to the NCBI Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/) under SuperSeries
accession no. GSE17593.]
Cancers arise from the accumulation of genomic mutations and
epigenetic changes that alter gene function and expression. In re-
cent years,many new oncogenes and tumor suppressor genes have
emerged from genome-wide analyses of human cancers (Stratton
et al. 2009). Collectively, somatic base-pair mutations have been
identified in many human genes through targeted DNA sequenc-
ing efforts (Forbes et al. 2008). DNAmicroarrays have been used to
measure gains and losses in DNA copy number, as well as altered
gene expression profiles. These efforts have provided key insights
into the underlying biological mechanisms driving tumorigenesis.
Additionally, they enable classification of patient subpopulations
and the discovery of prognostic and predictive biomarkers (Sawyers
2008), inspiring the design of novel targeted approaches for clinical
intervention (Stuart and Sellers 2009).
Despite their widespread utility, standard microarray and se-
quencing technologies have shown limited ability to interrogate
key mRNA-based events such as gene fusions, alternative splicing,
and base mutations involving the entire expressed fraction of the
cancer genome. Gene fusions, in particular, have been recognized
as a common and important feature of cancer since the discovery
and characterization of the Philadelphia chromosome (Nowell and
Hungerford 1960; Rowley 1973). Arising from translocations and
other chromosomal abnormalities, gene fusions have been most
commonly associated with hematological disorders and soft tissue
sarcomas (Mitelman et al. 2007). Recent discoveries of prominent
recurrent gene fusions in prostate cancer (Tomlins et al. 2005) and
lung cancer (Soda et al. 2007) have revealed their prevalence in
epithelial carcinomas as well (Prensner and Chinnaiyan 2009).
That these recurrent events in epithelial carcinomas had gone un-
discovered for so long is due to the fact that the technologies to
systematically interrogate the genome for such alterations have
emerged only recently. This raises the possibility that tumor types
for which virtually no gene fusions are known, such as melanoma,
may harbor important aberrations that can be identified by the
application of these genomic tools.
Massively parallel sequencing technologies (Shendure and Ji
2008) offer the opportunity to characterize the cancer genome at
unprecedented depth and sensitivity. Large-scale transcriptome se-
quencing (RNA-seq) using short paired-end reads has proved an
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effective means of precisely denoting exon structure and identify-
ing novel transcription in a large variety of species (Cloonan et al.
2008; Lister et al. 2008; Morin et al. 2008; Mortazavi et al. 2008;
Nagalakshmi et al. 2008; Sultan et al. 2008; Hillier et al. 2009;
Yassour et al. 2009). Gene expression estimates from short-read se-
quencing have been shown to recapitulate microarray-based mea-
surements (Marioni et al. 2008), while providing additional infor-
mation regarding the existence and abundance of alternatively
spliced variant transcripts (Pan et al. 2008; Wang et al. 2008). Gene
fusions and other chimeric transcripts have been identified by RNA
sequencing in selected prostate and breast cancer cell lines using
technologies that generate single long reads spanning the fusion
points (Maher et al. 2009a; Zhao et al. 2009). Paired-end short-read
sequencing of RNA offers a particularly sensitive and efficient ap-
proach to gene fusion discovery due to the larger number of distinct
reads and the increased physical coverage resulting from the long
fragment length (Maher et al. 2009b). The millions of paired-end
reads generated in a single lane of an Illumina Genome Analyzer II
enable the additional characterization of gene expression levels, al-
ternative splicing, sequencemutations, and allele-specific expression.
Here, we present a systematic framework for the integrative
genomic analysis of cancer transcriptomic data. Using paired-end
RNA-seq data from 10 patient-derived melanoma short-term cul-
tures and cell lines, we discovered 11 novel expressed gene fusions
produced by underlying genomic rearrangements, representing, to
our knowledge, the first gene fusions reported in melanoma. We
mapped these transcripts to base-pair resolution and interrogated
their genomic origins using sample-matched high-density SNP
array and chromosomal data. We also discovered 12 novel chi-
meric readthrough transcripts, including seven that were found in
multiple melanoma samples. Further, we used the RNA-seq data to
simultaneously interrogate sequence mutations, gene expression
levels, alternative splicing, and allele-specific expression. These
analyses have identified numerous novel genetic events in mela-
noma that offer several new biological insights into this malig-
nancy and can be prioritized for further functional characteriza-
tion. More generally, these results provide a template for the sys-
tematic analysis of transcriptomic data across broad collections of
tumors.
Results
A framework for systematic cancer transcriptome analysis
To test the robustness of RNA-seq for transcriptome characteriza-
tion in cancer, we performed paired-end RNA-seq using a cDNA
library prepared from the well-characterized chronic myelogenous
leukemia (CML) cell line K-562, which harbors the BCR-ABL1
gene fusion. Following cDNA library construction and shearing
(Methods), fragments were size-selected to a fragment length range
of 400–600 base pairs (bp) and loaded into separate flow-cell lanes
on an Illumina Genome Analyzer II. We obtained 15.5 million
pairs of 51-mer reads (8.8million purity filtered pairs; Bentley et al.
2008), or 1.6 gigabases (Gb) of total sequence.
Next, we sought to implement an alignment strategy for
RNA-seq read pairs that enabled identification of multiple types
of mRNA alterations at optimal sensitivity and specificity (Sup-
plemental Fig. S1). Here, all sequence reads were independently
aligned to a reference consisting of the transcriptome (61,478
human transcripts in the Ensembl database) and the human ge-
nome (hg18), as described inMethods. This approach ensures that
both annotated splice junctions and unannotated transcribed re-
gions are accessible; reads encompassing splice junctions are split
and then mapped to their genomic coordinates. For a read pair to
be informative, we required a unique genomic placement for each
read, and we eliminated duplicate pairs likely arising from PCR in
library construction. As a result, we considered 4.0 million distinct
read pairs informative for further analysis in K-562, achieving a
mean sequence coverage of 4.43 for the annotated transcriptome
(Supplemental Table S1). This two-tiered alignment and data fil-
tering method markedly reduced the fraction of false-positive
events detected by RNA-seq.
We reasoned that the gene fusions could be recognized by
the presence of discordant read pairs in which each end mapped
to a different chromosomal locus. However, we anticipated that
artifactitious discordant read pairs could also arise from errors in
sequence alignment, and that even a lowmisalignment rate would
overwhelmour ability to discern bona fide gene fusions. Therefore,
we limited our analysis to cases with (1) read pairs mapping uni-
quely in thehumangenome toopposite strandsof separate protein-
coding genes and (2) at least one 51-base read unambiguously
spanning a junction between two exons of the genes.
As a positive control, we looked for reads connecting BCR
on chromosome 22 and ABL1 on chromosome 9. We observed 37
distinct read pairs with ends mapping to the two genes, as well as
23 individual fusion-spanning reads, implicating a fusion between
exon 14 of BCR and exon 2 of ABL1 (Supplemental Fig. S2). In
addition to BCR-ABL1 we found two more gene fusions meeting
these criteria (NUP214-XKR3 and BAT3-SLC44A4; Supplemental
Fig. S3). We subsequently validated these gene fusions by RT-PCR
and Sanger sequencing (Supplemental Fig. S4).
Having demonstrated the effectiveness of the technique for
K-562, we then applied the method to 10 melanoma specimens
(eight patient-derived short-termcultures and two cell lines,MeWo
and 501 Mel). In addition to mRNA, we isolated genomic DNA
from eachmelanoma, including matched normal DNA from three
patients, to interrogate the genomic alterations underlying any
events we observed from RNA-seq.We obtained one lane of mRNA
sequence for each specimen, yielding an average of 14.2 million
pairs of 51-mer reads, or nearly 1.5 Gb of total sequence per sample
(Supplemental Table S1).
We analyzed the data to identify gene fusions, chimeric
readthrough transcripts, and point mutations, as described below.
We also determined gene expression levels and identified instances
of alternative splicing and allele-specific expression for the entire
melanoma transcriptome as a whole (described in Supplemental
material). Altogether, these efforts provide a framework for the
systematic integrated analysis of paired-end RNA-seq data.
Novel gene fusions in melanoma
Using the criteria above, we identified 11 novel gene fusions
(Figure 1; Table 1), and successfully validated all 11 using RT-PCR
followed by Sanger sequencing across the fusion point (Supple-
mental Fig. S5). Of these 11 fusions, four involve genes on separate
chromosomes, and seven represent intrachromosomal events. All
11 gene fusions appear to be heterozygous based on the presence
of reads consistent with the normal gene structure as well (Sup-
plemental Table S2). To verify that these gene fusions arose from
physical rearrangements in the genome, we tested 10 of 11 cases
by performing long-range PCR with genomic DNA followed by
end-sequencing of products. In nine of 10 cases, we confirmed
the presence of a genomic rearrangement (Supplemental Table S3).
The inability to detect a genomic rearrangement in the remaining
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Figure 1. Gene fusions in melanoma. (A) RB1-ITM2B gene fusion in short-term culture M990802. ITM2B is transcribed immediately upstream of RB1 on
chromosome 13, yet in M990802, a fusion transcript beginning with the 59 end of RB1 and ending with the 39 end of ITM2B is implicated by 14 distinct
read pairs and two individual fusion-spanning reads. (B) RECK-ALX3 gene fusion in short-term culture M000921. Two alternate transcripts are observed in
the RNA-seq data: One joining exon 13 of RECK to exon 3 of ALX3, and one joining exon 14 of RECK to exon 3 of ALX3. (C ) Spatial distribution of sequence
reads for RECK and ALX3 are consistent with a fusion transcript containing the 59 end of RECK and the 39 end of ALX3.
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case is likely due to inefficient long-range PCR; however, we cannot
exclude the possibility that this gene fusion may have arisen from
trans-splicing (Li et al. 2008).
Based on current knowledge about mutations in cancer, it is
expected that themajority of these gene fusionsmay be ‘‘passenger’’
mutations (Stratton et al. 2009). In the absence of directed func-
tional follow-up experiments, one cannot distinguish ‘‘driver’’ from
passenger mutations. Nonetheless, the genes implicated in these
fusions include several geneswithprevious associationswith cancer.
One gene fusion involves RB1, a well-characterized tumor
suppressor gene. While deletions, truncations, and mutations of
RB1 have been observed in many cancers, translocation is not a
known mechanism for the disruption of RB1 function (Futreal
et al. 2004). In this case (melanoma short-term culture M990802),
the N terminus of RB1 is joined to the integral membrane protein
ITM2B in an in-frame fusion. Of note, these genes are adjacent on
chromosome 13 and transcribed in the same orientation, but RB1
normally lies downstream of ITM2B (Fig. 1A). The RNA-seq data
also reveal an apparently full-length intact RB1 transcript at nor-
mal expression levels. Thus, if the fusion gene, in fact, is a driver
mutation, it might therefore act in a dominant negative manner.
We also observed an in-frame fusion involving theDNA repair
gene PARP1 (PARP1-MIXL1) in melanoma cell line 501 Mel, which
may lead to genomic instability through loss of PARP1 function.
The fusion product contains nearly the whole DNA-binding do-
main of PARP1, yet is missing the entire catalytic domain. If the
fusion is a driver mutation, it thus might also act in a dominant
negative manner.
Several other fusions also involved cancer-related genes. A
RECK-ALX3 fusion is produced by a translocation between chro-
mosomes 9 and 1 in melanoma short-term culture M000921 (Fig.
1B). ALX3 encodes a homeobox transcription factor, while RECK
is an inhibitor of tumor invasion and metastasis (Takahashi et al.
1998). The TLN1 gene (present in the TMEM8B-TLN1 fusion) is
present within a focal genomic amplification observed in oral
squamous cell carcinoma (Snijders et al. 2005). CCT3 and GNA12
(implicated in the CCT3-C1orf61 and GNA12-SHANK2 fusions, re-
spectively, both ofwhichoccur in the 501Mel cell line) function in a
cellular network predicted to play a role in colorectal cancer (Nibbe
et al. 2009). On the other hand, several gene fusions involve poorly
characterized genes or genes with no previous ties to cancer.
Despite the associations above, a causal role for these fusions
in melanoma remains speculative until the appropriate functional
experiments are performed. Nonetheless,
the RNA-seq data directly pinpoint in-
teresting candidate fusion events and
thereby define functional experiments to
interrogate their functional roles.
DNA and mRNA structural variations
associated with melanoma gene fusions
The RB1-ITM2B and RECK-ALX3 gene fu-
sions also exemplified interesting struc-
tural features observed repeatedly among
the 11 events we discovered. RB1-ITM2B
represents one of four cases where adja-
cent genes transcribed in the same orien-
tation occur out of order in the fusion
transcript. That is, the 59 gene in the fu-
sion transcript (RB1) actually lies 39 of its
partner (ITM2B) in the normal human
genome. Such events may arise from tandem duplications, posi-
tioning the 39 end of the first gene downstream of the 59 end of the
second gene (Fig. 1A). We examined this hypothesis using SNP
microarrays to measure DNA copy number, as discussed below.
The RECK-ALX3 fusion represents one of two cases where the in-
dividual fusion-spanning sequence reads indicate the presence of
multiple alternatively spliced isoforms involving separate fusion
points.We identified two sets of reads joining RECK and ALX3: Four
reads joining exon 14 of RECK to exon 3 of ALX3, and two reads
joining exon 13 of RECK to exon 3 of ALX3 (Fig. 1B). We also found
reads implicating separate transcripts involving exon 4 of CCT3
fused to multiple exons of C1orf61 (data not shown). Our data are
consistent with a single genomic breakpoint after exon 14 of RECK
and before exon 3 of ALX3, leading to alternatively spliced fusion
transcripts spanning this breakpoint. As shown in Figure 1C, the
observed sequence coverage from RNA-seq confirms elevated ex-
pression of the 59 end of RECK and the 39 end of ALX3 in short-term
culture M000921.
To study at higher resolution the underlying genomic changes
producing these chimeric transcripts, we hybridized genomic DNA
to Affymetrix SNP 6.0 microarrays for three melanomas harboring
multiple gene fusions (eight gene fusions total). These SNP arrays
enable the measurement of DNA copy number at more than 1.8
millionmarkers across the genome (McCarroll et al. 2008). Although
gene fusions are not necessarily expected to be accompanied by
underlying chromosomal changes (for instance, balanced trans-
locations are copy-neutral alterations) we nevertheless observed
clear changes inDNAcopynumber (mostly amplifications) for seven
of eight cases, with well-defined breakpoints evident within both
genes for six fusions. As shown in Figure 2A, SNP arrays revealed
copy number breakpoints within RECK and ALX3 at the exact po-
sitions expected from the observed fusion transcript. We confirmed
the disruption of both loci using fluorescence in situ hybridization
(FISH), as shown in Figure 2B. The SNP array results also support the
hypothesis that intrachromosomal gene fusionsmay originate from
tandem duplications (Campbell et al. 2008). For example, small
amplified regions were observed for the loci producing RB1-ITM2B
(chromosome 13) and ANKHD1-C5orf32 (chromosome 5). The
boundaries of these regions are entirely consistentwith the chimeric
transcripts observed for each pair of genes (Fig. 2C,D).
In three cases, we used Sanger sequencing to map the geno-
mic breakpoints to base-pair resolution, as shown in Figure 3.
We confirmed the precise location of the breakpoint producing
Table 1. Novel melanoma gene fusions
Sample 59 Gene Chromosome 39 Gene Chromosome
No. of
read
pairs
No. of
fusion-spanning
reads
Reading
frame
501 Mel CCT3 1 C1orf61 1 55 18 In-frame
501 Mel GNA12 7 SHANK2 11 18 4 In-frame
501 Mel SLC12A7 5 C11orf67 11 32 23 In-frame
501 Mel PARP1 1 MIXL1 1 2 4 In-frame
M000216 KCTD2 17 ARHGEF12 11 3 2 Out-of-frame
M000921 TMEM8B 9 TLN1 9 2 1 In-frame
M000921 RECK 9 ALX3 1 23 6 Out-of-frame
M010403 SCAMP2 15 WDR72 15 2 2 In-frame
M980409 GCN1L1 12 PLA2G1B 12 3 2 Out-of-frame
M990802 ANKHD1 5 C5orf32 5 9 20 Out-of-frame
M990802 RB1 13 ITM2B 13 14 2 In-frame
Novel gene fusions harboring at least two distinct discordant read pairs and at least one fusion-span-
ning individual 51-mer read are shown. Each gene fusion was validated by RT-PCR followed by Sanger
sequencing of the product.
Berger et al.
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RB1-ITM2B to occur within the second intron of RB1 and the
second intron of ITM2B. Another potential tandem duplication
producing TMEM8B-TLN1 was mapped to the expected introns.
Finally, we identified the translocation sitewhere chromosomes 17
and 11 are joined to produce KCTD2-ARHGEF12. In all three cases,
the fused chromosomes involved uninterrupted stretches of native
sequence from each locus joined at a single position, suggesting
a clean break and reattachment for each chromosomal event.
Observed gene fusions appear to be private
or low frequency events in melanoma
In principle, melanoma gene fusions may represent important
driver events directing tumor progression. Such driver events
might be expected to occur repeatedly in multiple independent
melanomas. However, no fusion transcript resulting from an un-
derlying chromosomal alteration was observed in more than one
instance of the 10 samples analyzed by RNA-seq. We further
screened for the presence of each fusion event by RT-PCR in 90
additional melanoma cell lines and short-term cultures derived
from patients with metastatic disease. Each fusion product was
detectable only in the original sample from which it was discov-
ered and not in the additional 90 (data not shown). While these
results do not exclude the possibility of gene fusions involving
alternate partners, or even alternate exons within the same pairs of
genes, we were unable to demonstrate the presence of any partic-
ular DNA rearrangement-driven fusion transcripts in more than
one sample. Based on these results, the translocation-based gene
Figure 2. Genomic aberrations leading to gene fusions. (A) Evidence for copy number breakpoints inside RECK and ALX3 from Affymetrix SNP 6.0
microarrays. Raw probe signals were normalized (spots) and segmented (lines) as described in Methods. Exons in red represent those occurring in the
RECK-ALX3 fusion transcript. (B) FISH in short-term culture M000921 at the RECK and ALX3 loci. Probes positioned 100–200 kb on both sides of each gene
reveal amplifications 59 of RECK and 39 of ALX3. (C ) Amplification involving ITM2B and RB1 on chromosome 13. A tandemduplication would position exon
2 of RB1 upstream of exon 3 of ITM2B (red), as observed in the fusion transcript. (D) Amplification involving C5orf32, ANKHD1, and intervening genes. A
tandem duplication would position exon 1 of ANKHD1 upstream of exon 3 of C5orf32 (red), as observed in the fusion transcript.
Integrative analysis of the melanoma transcriptome
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fusionswe discovered appear to be private events inmelanomas (or
else occur at very low frequencies). This suggests that many of
these events may therefore constitute passenger mutations with
little consequence for tumorigenesis. The apparent absence of any
common, highly expressed gene fusions in melanoma is itself
notable, suggesting that the underlying carcinogenic mechanisms
pertinent to melanoma may differ from other tumor types with
common gene fusions, such as prostate cancer and many hema-
tologic malignancies.
It is conceivable that for some gene fusions, one or both
constituent partner genes may represent bona fide cancer genes
that are more commonly altered by other genetic mechanisms;
e.g., prevalent amplification or deletion
events. To explore this possibility, we in-
tegrated our gene fusion results with
existing melanoma chromosomal copy
number data. Specifically, we wished to
determine if any fusion partner genes
identified here localized to genomic re-
gions previously shown by our group to
undergo statistically significant copy
number alterations in melanoma (Lin
et al. 2008). Of the 22 partner genes (Table
1), one gene (KCTD2) localized to a sig-
nificant region of copy gain, and two
genes (RB1 and ITM2B; comprising a sin-
gle intrachromosomal fusion event) lo-
calized to a significant region of copy loss.
We then focusedour attention on the
RB1-ITM2B fusion transcript. In a previous
analysis of chromosomal copy number
data sets derived from 70 primary cuta-
neous melanomas (Curtin et al. 2005), a
region on chromosome 13q encompass-
ing the RB1/ITM2B locus was shown to be
significantly deleted, second only to the
ARF locus amongst melanoma chromo-
somal deletions (Fig. 4A; Lin et al. 2008). The ARF locus includes
CDKN2A (encodes the p16 protein), a common melanoma tu-
mor suppressor that up-regulates the retinoblastoma (RB1) path-
way through suppression of cyclin/CDK function. In light of this
functional overlap betweenCDKN2A and RB1 deletion, RB1might
seem to be an unlikely target gene of 13q deletion in melanoma.
However, our data raise the possibility that dysregulation of RB1 is
indeed a target of 13q deletion, representing a driver mechanism
independent of CDKN2A deletion. Toward this end, the RB1-
ITM2B fusion occurs together with CDKN2A deletion in the
M990802 short-term culture (not shown). Furthermore, deletions
involving the RB1 and CDKN2A loci co-occur at a statistically sig-
nificant frequency in the aforementioned 70 primary cutaneous
melanomas (P = 0.022; Fig. 4B). Conceivably,CDKN2A and RB1may
exert partially distinct functional roles as melanoma tumor sup-
pressor genes. We emphasize that, alone, these results are in-
sufficient todistinguishdriver frompassenger events; however, they
illustrate how the integration of RNA-seq with orthogonal genomic
data sets can identify candidate driver events for directed functional
experiments.
Chimeric readthrough transcripts are recurrent in melanoma
In the analysis above, we specifically focused ongene fusions arising
from chromosomal aberrations (i.e., involving genes on different
chromosomes or in unexpected orientations on the same chromo-
some). However, we also observed evidence of ‘‘readthrough’’ tran-
scripts joining nearby genes transcribed in the same orientation.
We identified 49 cases of transcripts involving distinct genes in
the Ensembl database, based on the presence of at least two read
pairs connecting the genes and at least one unambiguous individual
fusion-spanning read. To eliminate possible errors in gene structure
annotation or cases of incomplete transcriptional termination in
normal cells, we eliminated 22 cases inwhich the genes were joined
in other databases and 15 cases in which the genes were joined in
reported EST sequences derived from nonmelanoma human tissues
and cell lines.
Figure 3. Genomic breakpoints mapped to base pair resolution. The
precise locations of the fusion points in the genomic DNAwere determined
by Sanger sequencing for three gene fusions: RB1-ITM2B, TMEM8B-TLN1,
and KCTD2-ARHGEF12.
Figure 4. Co-occurrence of CDKN2A and RB1 deletions. (A) Array CGH copy number profiles for 70
primary cutaneous melanomas (Curtin et al. 2005). Blue segments correspond to deleted regions, and
red segments correspond to amplified regions. (B) Deletions at both loci (CDKN2A and RB1) were found
to significantly co-occur (P = 0.022).
Berger et al.
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The remaining 12 cases appear to represent novel read-
through transcripts (Table 2). Five of these events are predicted
to generate in-frame proteins; two leave the complete coding se-
quence of the initiating transcript intact, and the remaining
five, though out-of-frame, add additional residues to the initiating
transcript (average 21 amino acids). For seven of the 12 cases, we
detected supporting RNA-seq read pairs in at least two of the sam-
ples studied, indicating that these chimeric transcripts may rep-
resent recurrent events in melanoma.
Tumor-specific readthrough transcripts have previously been
linked to other cancers, such as prostate cancer (Maher et al.
2009a); thus, it is conceivable that at least some of the events
discovered here may also contribute to tumorigenicity in mel-
anoma. We note that one novel readthrough transcript, CDK2-
RAB5B, was found in four of 10 melanoma RNA-seq samples
(Fig. 5A; Table 2). CDK2 encodes a protein kinase that is a critical
regulator of the G1/S phase transition of the cell cycle. The trans-
lated product of the readthrough transcript, which is identical in
all four melanomas, consists of the first 264 of 298 amino acids of
CDK2, followed by only two additional residues. This results in
a premature truncation of the kinase do-
main by 22 amino acids, including de-
letion of the conserved arginine in sub-
domain XI, though the effect of this
alteration on kinase activity is unclear.We
found additional read pairs supporting
the CDK2-RAB5B readthrough transcript
in three more melanomas. Of note, CDK2
expression is elevated in the seven sam-
ples for which the readthrough was de-
tected (Fig. 5B). The observation raises the
possibility that elements in the newly
added 39 untranslated region (UTR) of
the fusion transcript could contribute to
mRNA stability and post-transcriptional
regulationofCDK2 and, in turn, influence
cellular proliferation.
Some readthrough transcripts may
reflect low-level transcriptional read-
through in normal cells. However, we
note that we did not detect read pairs
connecting CDK2-RAB5B in the K-562
data set or RNA-seq data from primary
glioblastoma and ovarian tumors sequenced through a separate
effort (data not shown). These results raise the possibility that
CDK2-RAB5B is both recurrent in and specific to the melanocyte
lineage in general and melanoma in particular. They also un-
derscore the future necessity of deploying RNA-seq across many
additional tumors and cell types to characterize chimeric tran-
scripts systematically and discern cancer-specific events. Such ef-
forts will also lead to improved gene annotations and improve
understanding of transcriptome regulation.
Somatic mutation discovery in melanoma
by transcriptome analysis
In addition to mapping chimeric transcripts, RNA-seq provides
sequence-level information for each individual transcript. Whereas
several groups have developed methods for targeted high-through-
put sequencing of genomic DNA by first capturing genomic regions
of interest (typically exons) using molecular inversion probes
(Porreca et al. 2007; Krishnakumar et al. 2008), microarray-based
capture (Albert et al. 2007; Hodges et al. 2007; Okou et al. 2007), or
Table 2. Novel melanoma readthrough transcripts
59 Gene 39 Gene Chromosome Reading frame
Strong evidence
(two read pairs, one
junction read)
Supporting
evidence
(one read pair)
C11orf51 C11orf59 11 In-frame M990514
CCDC15 SLC37A2 11 Out-of-frame M980409 M990514, M990802
CD151 TSPAN4 11 CDS intact M990514
CDK2 RAB5B 12 Out-of-frame MeWo, M980928,
M980409,
M970109
M000216, M990802,
501 Mel
CLTC TMEM49 17 In-frame M980409 M980409
FOXRED2 TXN2 22 Out-of-frame MeWo M980928, M990514,
M970109, K-562
GPR153 ICMT 1 In-frame M990514 M000921
HOXB9 HOXB7 17 In-frame M990514
PFKFB4 SCOTIN 3 Out-of-frame MeWo M990514, M990802,
M970109
PTPRG C3orf14 3 Out-of-frame M990514
RBM35A DPY19L4 8 CDS intact M000921 M970109
WDR35 TTC32 2 In-frame M990514
Novel readthrough transcripts harboring at least two distinct discordant read pairs and at least one
junction-spanning individual 51-mer read in at least one melanoma sample are shown. No evidence of
transcripts joining these genes was found in existing gene and EST databases.
Figure 5. Novel recurrent readthrough transcript. (A) CDK2-RAB5B, shown here for the MeWo cell line, was independently discovered in four mela-
nomas, with supporting evidence observed in three more. In MeWo, CDK2-RAB5B is implicated by eight distinct read pairs and 10 individual junction-
spanning reads. (B) Expression level of CDK2 as measured by RNA-seq for 10 melanomas. RPKM, reads per kilobase of exon model per million mapped
reads (Mortazavi et al. 2008).
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solution-phase hybrid selection (Gnirke et al. 2009), RNA-seq offers
a systematic means to determine sequence mutations in expressed
protein-coding transcripts without the need for additional selection
steps (Sugarbaker et al. 2008).
The ability to detect mutations from RNA-seq data depends
heavily on the expression levels of the underlying genes. We found
that the proportion of transcripts in each sample covered an average
depth per nucleotide of at least 10-fold ranged from 5% to 17%
(Supplemental Fig. S6). By analyzing these data, we generated
sequence calls at anaverageof 4.7millionbasesper sample inprotein-
coding regions (Methods). We then compared the sequence calls to
the human reference sequence (hg18) to identify high quality variant
calls.We estimated that the sensitivity for detecting variant sequences
is ;75% of that for calling reference genotypes.
These variants identified by comparison to the human refer-
ence sequence are expected to consist of (in descending order
of frequency) inherited polymorphisms, somatic mutations, se-
quencing errors and bona fide differences between RNA and DNA
(e.g., RNA editing and polyadenylation). The rate of single nucleo-
tide polymorphisms (SNPs) in protein-coding regions of humans of
Europeandescent is;63 104 and, at present, roughly 94%of SNPs
found in a sample are already present in the dbSNP database (Sherry
et al. 2001;Ng et al. 2009). In contrast, the rate of somaticmutations
in most cancer types is typically 1–2 3 106. By comparing the tu-
mor sample to matched normal tissue from the same patient, one
can eliminate the inherited polymorphisms that are found in both.
Based on the reported polymorphism rates in coding regions
(;6 3 104), the average amount of coding sequence called per
sample (;4.7 million bases), and the estimated difference in sen-
sitivity (;75%), we would expect to find ;2100 variants per
sample, with 94% in current databases. In fact, we found 1694
variants per sample, with 93% in current databases. This discrep-
ancy likely results from regions of loss-of-heterozygosity in cancer.
Approximately 130 variants per sample were novel, with most
expected to be inherited SNPs.
To distinguish between novel inherited SNPs, somatic muta-
tions, and false-positive calls, we selected 103 randomly chosen
novel variants (including 95 nonsynonymous substitutions) in two
of the melanoma samples and genotyped them in tumor and
matched normal DNA. We observed that >95% were present in the
tumor DNA, which is considerably higher than that obtained in
previous RNA-seq studies (Sugarbaker et al. 2008) and that 67% of
these were also present in thematched normal DNA, indicating that
they are new inherited SNPs. The remainder is somatic mutations
(Fig. 6A). This implies a somaticmutation rate of 1.13 105.Wenote
that one cell line (MeWo) had more than twice as many novel var-
iants as any other sample, raising the possibility that this melanoma
harbors a ‘‘mutator’’ phenotype reflecting past exposure to UV ra-
diation or possible treatment of the patient with an alkylating agent.
The remaining samples exhibit a somatic mutation rate of 83 106,
which is four- to eightfold higher than the rate in typical cancers.
Previous sequencing efforts have also reported a markedly
higher mutation rate for melanoma compared to other cancers
(Greenman et al. 2007), with the excess explained by CG ! TA
transitions, which are typical of UV-inducedmutations (Drobetsky
et al. 1987). Among the validated somatic mutations identified
here, 86% consist of CG ! TA transitions, compared to 41% of
somatic point mutations previously reported for all non-skin
cancers (Fig. 6B; Forbes et al. 2008; P < 105; x2 test of homoge-
neity). An increase in the proportion of CG!TA mutations from
41% to 86% would require a 8.5-fold increase in such mutations
and would yield a fourfold increase in the total mutation rate. In
short, the data support the idea that melanomas have an unusually
high base-pair mutation rate, attributable to UV exposure. In addi-
tion, our data suggest a transcription-dependent mechanism of
mutation and/or mismatch repair—in as much as novel C ! T
variants occur much less frequently on the transcribed than non-
transcribed strand (72%:28%), whereas knownC! T SNPs detected
in these melanomas show no such bias (Vrieling et al. 1991).
In all, we validated 27 novel somatic missense mutations
involving genes listed in Table 3. Like the chimeric transcripts
above, the majority of these somatic mutations are expected to be
passenger events. However, several of these newmutations occur in
genes previously shown to be mutated in cancer (Cancer Genome
Atlas Research Network 2008; Forbes et al. 2008; Jones et al. 2008),
namelyA2M,CAST,CENTD3, FUS,NUP133, SF3B1, TNFRSF14, and
TRIB3 (Fig. 6A). Additionally, three genes with missense mutations
have previously been implicated in cancer-associated transloca-
tions: ETV5, CNBP, and FUS (Futreal et al. 2004). FUS (also named
TLS) is a DNA/RNA-binding protein that is involved in a gene fu-
sion with the CHOP transcription factor gene in some myxoid/
round cell liposarcomas (Rabbitts et al. 1993). FUS has also been
implicated in familial amyotrophic lateral sclerosis (ALS) through
the identification of 14 separate germlinemutations in the extreme
C-terminal domain in;25 families (Kwiatkowski et al. 2009; Vance
et al. 2009), and the somatic mutation that we observed (in mela-
noma short-term culture M970109) falls in the C terminus, very
close to this cluster of familial mutations. Interestingly, we ob-
served a validated mutation in another gene related to ALS: The
M000921 line harbors a somaticmutation in SETX, a genemutated
in families with juvenile ALS and spinocerebellar ataxia (Chen et al.
2004; Moreira et al. 2004). It is unclear whether this finding in-
dicates any connection between genes involved in melanoma and
those involved in motor neuron degeneration.
Altogether, we identified 721 novel, nonsynonymous coding
variants in melanoma (Supplemental Table S5), though only a
subset was subjected to validation to determine whether they are
bona fide somatic mutations. Based on the results above, we ex-
pected that most are inherited SNPs, whereas ;30% are somatic
mutations. Nonetheless, the set of variants is interesting. One
mutation observed in melanoma cell line 501 Mel (CTNNB1,
chr3:41241117, C!T) is noted 135 times in theCOSMICdatabase
of somatic mutations in cancer (Forbes et al. 2008). This mutation
changes serine 37 to phenylalanine in the beta-catenin protein,
and has been observed in a wide range of tissues, including 21 skin
cancer specimens. Another gene, SRRM2, harbors distinctmissense
variants in three out of 10 melanoma samples. Interestingly, the
MeWo melanoma cell line exhibits novel nonsilent variants in
two genes that are also implicated in the gene fusions above: A
missense mutation in ANKHD1 (p.P1808S) and a nonsense muta-
tion in SCAMP2 (p.Q301*). We confirmed the presence of both of
these mutations by genotyping. Because MeWo is an established
cell line with no matched normal DNA, we cannot determine
whether the mutations are germline or somatic. Nevertheless,
these observations lend support to the hypothesis that the genes
involved in fusions may be altered recurrently by various mecha-
nisms during the genesis or progression of melanoma.
Clearly, these melanomas also harbor many more somatic
mutations than can be discerned from our data—which only re-
liably cover ;12% of the protein-coding genes. For example, we
note that BRAF and NRAS, two commonly mutated melanoma
oncogenes, were not identified as mutated by this analysis because
these genes are not among the top ;12% of most abundant tran-
scripts in this data set. Technological improvements since these
Berger et al.
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data were generated have increased the sequencing output per
Illumina lane more than threefold, significantly expanding the
territory accessible to mutation discovery.
Gene expression-based alterations in melanoma
by transcriptome analysis
Last, we estimated gene expression levels and identified instances
of alternative splicing andallele-specific expression for themelanoma
transcriptome as a whole. These results (for more detail, see Sup-
plemental material) provide a framework for the systematic in-
tegrated analysis of paired-end RNA-seq data and further demon-
strate the utility of RNA-seq in interrogating the full spectrum of
RNA-based events relevant to cancer.
Briefly, we first quantified expression levels for all genes
in each sample according to the RPKMmeasure (reads per kilobase
of exon model per million mapped reads) (Mortazavi et al.
2008), reported in Supplemental Table S4, and observed high
reproducibility among replicate library construction and Illumina
sequencing experiments (Supplemental Fig. S7). Comparisons
Figure 6. Validation of somatic mutations. (A) Sequence variants in exon 16 of A2M in melanoma short-term culture M970109. Illumina 51-mer reads
are shown as gray boxes (arrowheads denote directionality of reads; nonreference bases are colored and shaded according to their quality scores). One
variant (T!C) is homozygous and corresponds to a known SNP in dbSNP (Sherry et al. 2001). The other variant (C!T) is heterozygous and corresponds
to a missense E624K mutation. This mutation was validated and confirmed to be somatic. (B) Distribution of transitions and transversions in sequence
variants genotyped by Sequenom. Validated somatic mutations were largely CG to TA transitions (86%), representative of mutations induced by UV
damage (Drobetsky et al. 1987). In contrast, only 53% of novel germline variants and 0% of variants that failed to validate were CG to TA transitions.
Thirty six percent of all known SNPs detected by Illumina in the 10 melanoma samples were CG to TA transitions with respect to human genome
reference hg18.
Integrative analysis of the melanoma transcriptome
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to microarray-based measurements of gene expression for
these melanomas revealed good agreement between these tech-
nologies, with RNA-seq exhibiting a much wider dynamic range
and greater precision for 97% of expressed genes (Supplemental
Figs. S8, S9).
By counting individual sequence reads spanning exon junc-
tions, we determined the relative abundance of different splice
isoforms (Supplemental Fig. S10). Moreover, we discovered 4313
novel exon junctions in 2932 genes, including 12 of the 22 genes
involved in the 11 gene fusions above.
We analyzed the data to look for instances of apparent allele-
specific expression in these 22 genes; we found compelling evidence
for allele-specific expression in one case: the gene SLC12A7 (Sup-
plemental Fig. S11). A more complete description of this analysis is
presented in Supplemental material.
Discussion
In this study, we have applied high-throughput paired-end se-
quencing of cDNA (RNA-seq) as a systematic means to identify
chimeric transcripts and other genetic alterations that are ex-
pressed in tumors. In so doing, we discovered 11 novel melanoma
gene fusions produced by underlying genomic rearrangements,
representing, to our knowledge, the first such events inmelanoma.
These fusions involve common cancer-related genes, such as RB1
and PARP1, as well as several genes with no known cancer associ-
ations. We mapped each fusion point to base pair resolution and
identified alternatively spliced fusion products in two cases. Fu-
sion transcripts were also typically accompanied by genomic copy
number alterations. Altogether, seven of the 11 fusions produced
in-frame ORF derivatives, though the specific biological conse-
quences of these events on melanoma genesis and maintenance
remain to be determined.
We obtained an average of 14.5 million paired-reads from
a single Illumina lane for each melanoma sample, which enabled
us to estimate transcript abundance, identify alternatively spliced
variants, and discover novel base pair mutations in addition to
gene fusions. Because only one lane is needed, this strategy can
readily be scaled up to interrogate multiple specimens of many
diverse tumor types. This attribute differs importantly fromwhole-
genome sequencing, which currently requires many dedicated
whole flow cells per sample in order to detect mutations (Ley et al.
2008; Mardis et al. 2009; Shah et al. 2009). Significant improve-
ments have been made in high-throughput sequencing technol-
ogy since these melanoma RNA-seq data were generated, enabling
even greater sequence coverage per lane of sequencing. In the fu-
ture, the use of DNA barcoding may allow multiple samples to
be pooled within a single lane for higher-throughput multiplexed
sequencing (Craig et al. 2008).
The sensitivity for detecting gene fusions by paired-end,
massively parallel sequencing depends onmany factors, including
expression level, transcript length, and cDNA library fragment
length.With about 3million distinct read pairs mapping uniquely
to annotated protein-coding genes in the Ensembl database (as
was obtained for a single Illumina lane of K-562 in this study), a
heterozygous fusion point could theoretically be detected by
our criteria in each of the top 50% of expressed genes with a
probability of $70% (Supplemental Fig. S12). The most biolog-
ically meaningful translocations are likely to be those that pro-
duce fusion transcripts expressed at appreciable levels; thus,
paired-end RNA-seq provides a robust means for identifying such
events.
This study demonstrates for the first time that gene fusions
and other chimeric transcripts occur frequently in melanoma. Al-
though gene fusions were traditionally associated with hemato-
logical disorders and soft tissue sarcomas, several recent reports of
recurrent gene fusions in prostate cancer (Tomlins et al. 2005) and
lung cancer (Soda et al. 2007) reveal them to be important driver
events of epithelial carcinomas aswell. The discovery of a recurrent
chimeric readthrough transcript involving CDK2 is noteworthy
in this regard. Expression of this cyclin-dependent kinase in mel-
anoma is regulated by MITF (Du et al. 2004), a master transcrip-
tional regulator of melanocyte development that also functions as
a melanoma oncogene (Garraway et al. 2005). In this context,
CDK2 was shown to be required for melanoma cell proliferation
(Du et al. 2004). The functional role(s) of truncated CDK2, when
expressed as a readthrough transcript, represents an interesting
area of further study.
All translocation-based gene fusions we discovered appear to
be private events, although it is possible that some represent driver
events. Overall, we observed that seven of 11 gene fusions produce
in-frameproducts. The fact that theRB1-ITM2B gene fusionmaps to
a region commonly deleted inmelanoma, raises the possibility that
inactivation of the retinoblastoma tumor suppressor may contrib-
ute tomelanoma pathology independent ofCDKN2A/ARF deletion.
If so, the observed co-occurrence ofCDKN2A and RB1deletionsmay
imply that tumors harboring both events could prove refractory
to pharmacologic CDK inhibition. Directed functional experiments
will be necessary to determine the biological importance of each
gene fusion and to delineate the possible mechanisms by which it
might influence or alter gene function.
In addition to discovering gene fusion events, we used
RNA-seq data to interrogate global properties of 10 melanoma
Table 3. Validated, novel somatic missense mutations
Gene Chromosome Position Nucleotide Protein
TNFRSF14 1 2486256 C! T V20L
DDOST 1 20851728 C! T G398D
CSDE1 1 115062791 C! A V741F
NUP133 1 227702133 G! A L190F
KIDINS220 2 8789087 T! C K1510R
SF3B1 2 197976666 G! T L536I
FAM116A 3 57606439 C! T R342H
CNBP 3 130372650 C! T G126E
ETV5 3 187305829 G! A P64S
LYAR 4 4336275 G ! A S32F
CAST 5 96115600 C! T P514S
CENTD3 5 141015630 G! A L1321F
CSNK2B 6 31744927 G ! A G123S
POPDC3 6 105713155 C! T G253E
SETX 8 134129888 G! A P2531L
LDB3 10 88467879 G ! A G509E
NAV2 11 20085892 G ! A E2320K
A2M 12 9139544 C! T E624K
ZNF828 13 114108194 C! T P259L
RAB11A 15 63956884 G ! A A68T
FUS 16 31109912 C! T P508S
HEATR3 16 48675575 C! T S388F
ZC3H18 16 87221873 G ! A R772K
TRIB3 20 325023 C! T A256V
ZNF337 20 25603846 C! T G693S
EIF3EIP 22 36584641 C! A F128L
CSTF2 X 99973216 C! T P316L
These 27 novel missense mutations were validated by an alternate gen-
otyping technology and confirmed to be present in the tumor DNA, but
not in matched germline DNA.
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transcriptomes. In doing so, we also directly examined many as-
pects of the 22 genes implicated in fusions. We discovered novel,
unannotated splice variants for 12 of these genes (described in
Supplemental materials). Additionally, we found that two of these
genes harbor nonsilent mutations in the melanoma cell line
MeWo. Although it is not possible to determine whether these
particular mutations are germline or somatic in origin (due to the
lack of a matched normal sample), they lend support to the hy-
pothesis that some fusion partner genes could represent mela-
noma oncogenes that become altered by multiple genetic means
during melanoma genesis.
We also discovered and validated 29 somatic mutations (27
missense) in the coding regions of additional genes. Although se-
quencing of many more samples is required to identify new genes
that are significantlymutated inmelanoma, we observedmutations
in several known cancer genes (or orthologs), as well as a potential
connection to neurodegenerative diseases. Regarding the latter, we
confirmed somaticmissensemutations in FUS and SETX in separate
samples; both genes are mutated in familial ALS (Chen et al. 2004;
Kwiatkowski et al. 2009; Vance et al. 2009). We also confirmed two
somatic mutations (one missense, one synonymous) in the gene
A2M (alpha-2-macroglobulin) in melanoma short-term culture
M970109. Alpha-2-macroglobulin, a plasma proteinase inhibitor,
mediates the degradation of A-beta in amyloid beta deposits, and
polymorphisms in A2M have been associated with susceptibility
to Alzheimer’s disease (Blacker et al. 1998). Further, ITM2B, which
is involved in a gene fusion, is a regulator of amyloid-beta pro-
duction, and mutations in ITM2B have been previously associated
with familial dementias similar to Alzherimer’s disease (Matsuda
et al. 2005). These data may provide a rationale for experimental
approaches to explore a possible connectivity between melanoma
genesis and mechanisms of neurodegeneration,
Extrapolating our empirical validation rates to all mutations
called fromRNA-seq,we estimate an average somaticmutation rate
of 8 3 106 in melanoma. This is notably higher than other can-
cers, yet explained by the large excess of CG! TA transitions in-
duced by UV exposure. Further, we observed a large variation in
average mutation rates across these melanomas—most strikingly
in the presence of one cell line with an especially high mutation
rate (mutator phenotype). Interestingly, we also detected more
gene fusions in one particular melanoma cell line (four fusions in
501Mel) than in any of the other short-term cultures. This cell line
also exhibits the largest number of copy number breakpoints de-
duced from SNP arrays, potentially indicative of excess genomic
instability.
In any given sample, we obtained sufficient sequence cover-
age to call genotypes at ;12% of bases contained in Ensembl
transcripts. Undoubtedly, many more nonsilent mutations are
present within the coding sequences of genes expressed at lower
levels. Notable examples include mutation BRAF and NRAS, two
known melanoma oncogenes that are not present in the top 12%
of most highly expressed genes in this data set. Our data suggest
that an additional fivefold to 10-fold more sequencing coverage
would be necessary to reliably identify mutations in the vast ma-
jority of genes. Given the rapid increase in sequencing output per
lane (threefold, just since these data were generated, with more in
prospect), it should be possible to obtain such coveragewith one to
two lanes of sequence on an Illumina sequencer. On the other
hand, targeted capture of genomic DNA or cDNA may be a more
effective strategy to discover mutations in genes that may not be
highly expressed (Levin et al. 2009). Thus, amixed strategy of RNA-
seq and targeted capture may prove optimal.
In conclusion, we have discovered 11 novel gene fusions and
12 novel readthrough chimeric transcripts in melanoma using a
paired-end,massively parallel sequencing strategy.We alsoused these
RNA-seq data to characterize the entire melanoma transcriptome
represented herein, including sequence mutations, gene expres-
sion levels, alternative splicing, and allele-specific expression. In
doing so, we demonstrate the capability of RNA-seq to interrogate
the full spectrum of RNA-based alterations relevant to cancer
through integrative analysis. This global approach can be readily
applied across broad panels of additional tumor types to search for
novel oncogenes and gene fusions. The therapeutic potential to
target gene fusions, as demonstrated by the success of imatinib
(Gleevec) in inhibiting the product of the BCR-ABL1 gene fusion in
CML (Kantarjian et al. 2002), further underscores the benefit and
importance of systematically deploying massively parallel se-
quencing technologies for comprehensive cancer genomic char-
acterization.
Methods
cDNA library construction
cDNA libraries were constructed for 10 melanoma samples (two
cell lines, eight patient-derived short-term cultures) and for the
CML cell line, K-562. Patient-derived short-term cultures origi-
nated from stage 4 tumors and were passaged 10–18 times in vitro
prior to RNA extraction (Supplemental Table S1). For each sample,
we removed DNA (Turbo DNA-free treatment, Ambion) and iso-
lated polyA+ RNA from 25 mg of total RNA. We synthesized cDNA
from 65 to 101 ng of polyA+ RNA, with a peak length of ;1500
bases using the SuperScript Double-Stranded cDNA Synthesis
kit (Invitrogen), SuperScript III Reverse Transcriptase (Invitrogen),
and 10 ng random hexamer primers (Invitrogen). Primer anneal-
ing was done at room temperature for 10 min followed by 1 h at
55°C for first strand synthesis and 2 h at 16°C for second strand
synthesis. Following second strand synthesis and cDNA clean-up,
each cDNA library was sheared by sonication with four alternating
cycles between ‘‘high intensity’’ (30 sec; duty cycle, 5%; intensity,
5%; cycles per burst, 200) and ‘‘low intensity’’ (5 sec; duty cycle,
1%; intensity, 1%; cycles per burst, 200) in the Frequency Sweeping
mode (Covaris S2 machine). Paired-end adapters for Illumina se-
quencing were added following Illumina protocols, except that
five times less adapter mix was ligated to the cDNAs. For PCR
amplification, between 6- and 12-mL gel size–selected DNA were
mixed with 20 mL of 103 PCR buffer, 10 mL of DMSO, 1.6 mL of 25
mMdNTPmix, 2 mL each of 25 mMPCR primer PE 1.0 and 2.0, and
2 mL of Herculase Hotstart DNA polymerase (Stratagene) in a final
volume of 200 mL. The samples were denatured for 5 min at 95°C;
18 cycles of 20 sec at 95°C, 30 sec at 65°C, and 30 sec at 72°C; and
final 7 min at 72°C to polish ends before cooling to 4°C. PCR
primerswere removed by using 1.83 volume of Agencourt AMPure
PCR Purification kit (Agencourt Bioscience Corporation). All mel-
anoma cDNA libraries were prepared with a fragment length range
of 400–600 bp; two libraries were prepared for K-562, exhibiting
shorter (300–400 bp) and longer (400–600 bp) fragments. Each
library was loaded into its own single Illumina flow cell lane,
producing an average of 14.5million pairs of 51-mer reads per lane
(8.4 million purity filtered read pairs), or nearly 1.5 Gb of total
sequence for each sample.
Alignment of reads to the transcriptome and genome
To estimate transcript abundances from these paired 51-mer reads, all
reads were independently aligned to a single reference file consisting
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of all human transcripts in Ensembl build 52 and the human ge-
nome (hg18). Alignments were performed using the Burrows-
Wheeler Alignment Tool (BWA), allowing up to four mismatches
with the reference (Li and Durbin 2009). Reads aligning to the
transcriptome were mapped to their genomic coordinates, and
alignments were considered unique if all placements to the refer-
ence arise from a single genomic locus. 68%of readsmapped to the
references with no more than four mismatches (81% of these cor-
responded to annotated genes in Ensembl).
Read pairs were considered informative if both reads in-
dependently aligned uniquely. Duplicate read pairs (originating
from a single original template molecule) were removed to leave
a single read pair per fragment. Both reads aligned to a single ge-
nomic locus in the expected orientation for >97% of informative
read pairs. These read pairs were used to identify somatic base-pair
mutations; the remaining read pairs were used to discover novel
chimeric transcripts (gene fusions).
Identification of candidate gene fusions
Read pairs were selected as candidate fusion events if both reads
mapped uniquely to different protein-coding genes, with one
originating from the transcribed strand and the other originating
from the antisense strand. (Reads mapping within 1 megabase
(Mb) on the same chromosome in the expected orientation were
temporarily set aside as possible unannotated transcripts or read-
through events.) Reads in discordant pairs were trimmed by 10
nucleotides (nt) at each end to 31 nt total and realigned to all
Ensembl52 transcripts using BWA, allowing up to four mis-
matches. Discordant read pairs for which trimmed reads could be
placed on a single gene were filtered out. To select the highest
confidence candidates for validation,we searched the set of 51-mer
reads that did notmap to Ensembl transcripts or to the genome for
the presence of at least one individual read containing a hypo-
thetical fusion point between any two exons in the corresponding
genes. (A reference file was created for each candidate gene fusion
consisting of all hypothetical junctions between an exon of the 59
gene and an exon of the 39 gene. Unmapped reads were screened
against this reference using BWA.) All events for which the posi-
tions of the read pairs and individual fusion-spanning reads were
consistent with a gene fusion were prioritized for further study.
This analysis revealed three high-confidence gene fusions in K-562
and 11 high-confidence gene fusions in melanoma.
To model the sensitivity for detecting gene fusions, we con-
sidered each gene in the Ensembl database (18,615 total) to harbor
a single fusion point (Supplemental Fig. S12). Using the observed
number of read pairs mapping to each gene in the K-562 sample,
the length of each transcript, and the average cDNA fragment
length amplified in an Illumina cluster, we calculated the proba-
bility of detecting this fusion point in each gene. We modeled the
number of read pairs mapping to each transcript as a Poisson dis-
tribution, the mapped position of read pairs as a uniform distri-
bution, and the cDNA fragment length as a Gaussian distribution
(428 6 105, as observed for K-562), and we postulated the break-
point to occur in only one of two copies of the gene.
Validation of gene fusions by RT-PCR and sequencing
Fusion candidates from the Illumina paired-end cDNA sequencing
data analysis were validated experimentally on the transcript level
by reverse transcriptase PCR (RT-PCR). Total RNA was extracted
from each tumor sample, and cDNA was synthesized from 5 mg of
RNA (Qiagen QuantiTect Reverse Transcription kit). Gene-specific
PCR primers were designed to flank the hypothesized fusion
breakpoints. Following PCR and gel electrophoresis, all RT-PCR
amplified bands were gel excised (Qiagen QIAquick Gel Extraction
kit) and subjected to Sanger sequencing. All 11 candidate mela-
noma gene fusions (including two splice isoforms for two separate
gene fusions) were confirmed using this approach. Primer se-
quences for RT-PCR are displayed in Supplemental Table S6.
Long-range genomic PCR
Gene fusionswere validated on the genomic level using long-range
PCR (LR-PCR). The breakpoints in genomic DNA producing the
observed fusion transcripts were hypothesized to occur in the in-
tron immediately following the upstream exon and the intron
immediately preceding the downstream exon. For each gene of a
given fusion pair, primers were designed along the genomic exon–
intron boundaries. If either intron exceeded 15 kilobases (kb),
primers were positioned in 15-kb increments. LR-PCR reactions
(TakaRa LA PCR kit) were performed according to the manufac-
turers protocols. Following gel electrophoresis, all LR-PCR ampli-
fied bands were gel excised (Qiagen QIAquick Gel Extraction kit)
and subjected to Sanger sequencing. Nine of 10 candidate fusions
tested were confirmed at the genomic level based on the mapping
of the end sequence products.
FISH
To assess for rearrangements of both the RECK and ALX3 loci, two
unique break-apart FISH assays were designed using bacterial
artificial chromosome (BAC) FISH probes to hybridize with the
neighboring centromeric and telomeric regions of each gene. BAC
clones were selected from the March 2006 build of the human
genome using the University of California, Santa Cruz Genome
Browser and were obtained from the BACPAC Resource Center
(CHORI). For ALX3, the centromeric BAC clone was biotin-14-
deoxycytidine triphosphate (dCTP)–labeled RP11-36L11 (eventu-
ally conjugated to produce a red signal), and the telomeric BAC
clone was digoxigenin-dUTP–labeled RP11-195M16 (eventually
conjugated to produce a green signal). For RECK, the centromeric
BAC clone was biotin-14-dCTP–labeled RP11-58A20 (red), and the
telomeric BAC clone was digoxigenin-dUTP–labeled RP11-112J3
(green). Probe preparation and hybridization procedure were per-
formed as previously described (Perner et al. 2008). Probes were
applied to preparations of M000921 preserved in 3:1 methanol:
acetic acid. Assays were analyzed under a 1003 oil immersion
objective using a fluorescence microscope (Olympus) equipped
with appropriate filters, a charge-coupled device camera, and the
Cytovision FISH imaging and capturing software (Applied Imag-
ing). For each case, at least 100 nuclei were analyzed.
Screening for recurrent translocations
After the candidate gene fusions were validated by RT-PCR, 90 ad-
ditional melanoma samples were screened for the presence of each
fusion. Of these samples, 39 were melanoma cell lines obtained
from commercial sources, and 51 were patient-derived melanoma
short-term cultures. The short-term cultures were kindly provided
by M. Herlyn (Wistar Institute) or prepared as described previously
(Hoek et al. 2008). RNA was extracted from each of these samples
and cDNA was synthesized, as described above. RT-PCR was per-
formed on each sample simultaneously in 96-well plate format us-
ing the primer pairs that were used to validate the fusions. cDNA
prepared from the original samples served as positive controls. We
were unable to detect recurrent fusions innew samples for any these
chimeric transcripts.
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SNP 6.0 arrays
DNA from melanomas M000921, M990802, and 501 Mel were
hybridized to Affymetrix SNP Array 6.0 microarrays concurrently
with 15 normal HapMap samples. SNP 6.0 data were processed
from raw CEL files to segmented copy number data as described
previously (Cancer Genome Atlas Research Network 2008). Briefly,
raw Affymetrix CEL files were converted to a single value for each
probe set representing a SNP allele or a copy number probe. Copy
numbers were then inferred based upon estimating probe set-
specific linear calibration curves, followed by normalization by
the most similar HapMap normal samples. Segmentation of
normalized log2 ratios was performed using the circular binary
segmentation (CBS) algorithm.
Identification of read-through transcripts
Read pairs were selected as candidate readthrough events if (1)
both reads mapped uniquely to different genes in Ensembl on the
same chromosome and transcribed in a consistent orientation, (2)
one read originated from the transcribed strand and the other read
originated from the antisense strand, and (3) reads mapped within
1 Mb of each other. All candidate readthrough transcripts impli-
cated by at least two distinct read pairs (244 total candidates) were
screened for unmapped 51-mer reads containing a hypothetical
fusion point between any two exons in the corresponding genes,
using BWA as above. Forty-nine candidates harbored at least one
fusion-spanning 51-mer read in a location consistent with the
observed read pairs. These 49 readthrough transcripts were man-
ually inspected in theUCSCGenomeBrowser for existing evidence
of transcription. Twenty-two corresponded to annotated genes in
other (non-Ensembl) databases and/or full-length humanmRNAs,
and 15 more were supported by spliced human ESTs in GenBank.
The remaining 12 are novel readthrough transcripts.
Co-ocurrence of RB1 and CDKN2A deletions
Array CGH copy number data sets for 70 primary cutaneous mel-
anomas (Curtin et al. 2005) were segmented using the GLAD
method (gain and loss analysis of DNA) as described previously
(Lin et al. 2008). For each sample, if the designated copy number
status of the corresponding closest marker exceeded a log2-ratio
threshold of 0.3, the locus was inferred to be deleted. Of the
seven samples with a deletion at the RB1 locus, five also harbored
deletions at CDKN2A (P = 0.022, x2 test of homogeneity).
Mutation calling
Read pairs where both reads aligned uniquely to the same chrom-
some in the proper orientation (with duplicate pairs removed) were
considered for sequence variant identification. Each position in an
Ensembl transcript was assigned a LOD score indicating the likely
accuracy of the call, according to the observed sequence cover-
age, allele distribution, base quality score, and reference genotype
(hg18). Of 69,511,900 bases in Ensembl transcripts, an average of
8,145,636 total bases (and 4,687,155 CDS bases) exhibited LOD > 5.
Bases that disagreed with the reference genome were classified as
known SNPs if present in dbSNP (Sherry et al. 2001) (build 130), or
novel variants.We estimated the sensitivity for calling nonreference
variants at 75% by comparing the rate of polymorphism at all high-
coverage positions ($503) to the rate of polymorphism at all posi-
tions where the genotype was called (LOD > 5). Novel variants were
discarded if they occurred in more than one sample (melanoma or
K-562). While it is possible that this filtering step may eliminate
bona fide recurrent variants, in practice, most recurrent events rep-
resent technical or analytical artifacts in this small discovery set.
Mutation validation by Sequenom
Candidate base pair variants called by RNA-seq were interrogated
using an independent mass spectrometric genotyping technology
(Sequenom iPLEX genotyping). Variants were amplified in multi-
plex PCR reactions consisting of up to 24 loci each, using 10 ng of
template DNA from a single melanoma sample. Single base ex-
tensionwas performed on the shrimp alkaline phosphatase treated
PCR product using iPLEX enzyme and mass-modified terminators
(Sequenom iPLEX-GOLD reagents kit). SpectroCHIPs with 384-
wells were analyzed by a MassArray MALDI-TOF Compact system
with a solid phase laser mass spectrometer (Bruker Daltonics Inc.).
The resulting spectra were called and analyzed by the SpectroTyper
v.4.0 software.
Assays were designed for 103 randomly chosen protein-coding
variants in two melanoma samples (and their corresponding nor-
mals), including 95 putative nonsynonymous coding mutations.
Additionally, two nonsynonymous variants in ANKHD1 and
SCAMP2 were tested in the unmatched melanoma cell line MeWo.
We observed an overall validation rate of 95% in the tumor DNA,
with 67% of these true variants also present in thematched normal
germline DNA. In all, we validated 29 novel somatic coding muta-
tions (27 nonsynonymous). (Eight assays were technical failures.)
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